AI GxP validation for regulated life sciences
Compliance

GxP vs GMP vs GLP vs GCP: What Each One Actually Covers

A side-by-side breakdown of the GxP disciplines: what each regulates, where they overlap, which one applies to your work, and the boundary mistakes that create audit findings.

Cybroscape Technologies8 min read

Key takeaway

A side-by-side breakdown of the GxP disciplines: what each regulates, where they overlap, which one applies to your work, and the boundary mistakes that create audit findings.

The short version: GxP is the category, and GMP, GLP and GCP are members of it. GMP governs how a product is manufactured. GLP governs non-clinical safety studies. GCP governs clinical trials in humans. They are not tiers of the same rulebook and they are not interchangeable — each was written by different regulators for a different activity, and each has its own inspection style.

Confusing them is common and consequential. Teams apply GLP language to a QC lab that is actually under GMP, or assume a GCP-trained monitor understands batch release. This guide sets out what each covers, where they genuinely overlap, and the boundary mistakes that turn into findings.

Side by side

GMP — Good Manufacturing Practice

Covers: everything involved in making a product — premises, equipment, materials, personnel, batch records, in-process control, packaging, release. Key question: was this batch made correctly and can you prove it? Unit of scrutiny: the batch. Where it lives: 21 CFR 210/211 in the US, EudraLex Volume 4 in the EU, ICH Q7 for active ingredients.

GMP is continuous. There is no start and end date; it applies to every batch, every day the facility operates. This is why GMP organisations carry the heaviest routine documentation burden of the three.

GLP — Good Laboratory Practice

Covers: non-clinical safety studies submitted to regulators — toxicology, safety pharmacology, and similar. Key question: can this study be reconstructed and relied upon? Unit of scrutiny: the study. Where it lives: 21 CFR 58 in the US, OECD GLP Principles internationally.

GLP is the most frequently misapplied of the three. It governs specific safety studies intended for regulatory submission — not laboratory work generally. Routine QC release testing in a manufacturing lab is GMP. Analytical method development is usually neither. The distinguishing features of GLP are the Study Director role and an independent Quality Assurance Unit, neither of which exists in GMP with the same meaning.

GCP — Good Clinical Practice

Covers: the design, conduct, monitoring, recording and reporting of trials in human subjects. Key question: were subjects protected and is the data credible? Unit of scrutiny: the subject and the trial. Where it lives: ICH E6(R3), 21 CFR 312 and 50/56 in the US, EU Clinical Trials Regulation 536/2014.

GCP is the only one with an explicit ethical mandate as its first principle. It is also the most distributed: the sponsor, the CRO, and every investigator site all carry obligations, and the sponsor remains accountable for work it does not directly perform.

Where they genuinely overlap

Four requirements appear in all three, which is why the collective term is useful at all.

  • Data integrity. ALCOA+ applies identically. An inspector examining a GCP source document and one examining a GMP batch record are applying the same underlying test.
  • Computerised system validation. A system supporting any of the three must be validated. Annex 11 and Part 11 apply across disciplines.
  • Qualified, trained personnel with documented evidence.
  • Change control and deviation management. The terminology shifts — GCP says protocol deviation, GMP says deviation and CAPA — but the obligation to detect, assess, document and act is common.

This overlap is what makes a shared platform practical. The same validated document control and audit trail infrastructure can serve all three, which is the usual argument for consolidating onto GxP software rather than running discipline-specific tools.

Where the differences actually bite

Who holds final accountability. In GMP it is the Qualified Person or equivalent, who personally certifies batch release. In GLP it is the Study Director, who has sole responsibility for the scientific conduct of the study. In GCP it is split — the sponsor holds overall responsibility, the principal investigator holds site-level responsibility for subject welfare. Applying one model to another discipline creates approval chains that do not match the regulation.

What an inspection looks like. A GMP inspection is a site inspection — the facility, the equipment, the records. A GLP inspection is usually study-based — reconstructing a specific study from raw data. A GCP inspection is often site-based at an investigator location, comparing case report forms against source documents. Preparation for one does not prepare you for another.

Retention periods. These differ materially by discipline and jurisdiction, and getting them wrong in either direction is costly. Covered in detail in GxP archiving and data retention.

The independent quality function. GLP requires a Quality Assurance Unit structurally independent of study conduct. GMP requires a Quality Unit with defined release authority. GCP has no exact equivalent — monitoring and audit serve a related purpose with a different structure.

The boundary mistakes that cause findings

  • Calling QC testing "GLP". The single most common error. Release testing in a manufacturing quality control lab is GMP. Claiming GLP status invites an inspector to look for a Study Director and a QAU that do not exist.
  • Treating clinical manufacturing as GCP-only. Investigational medicinal product is manufactured under GMP. A trial sponsor making its own supply is under both, and the GMP obligations do not soften because the material is for a trial.
  • One SOP set stretched across disciplines. A generic deviation procedure that ignores the difference between a protocol deviation and a manufacturing deviation produces records that satisfy neither inspector.
  • Assuming a vendor's GxP claim covers your discipline. A system validated for GMP document control is not automatically fit for trial master file obligations. Ask which discipline the vendor's evidence actually addresses — a point covered in qualifying an AI vendor and equally true of conventional software.
  • Uniform validation rigour across every system. Effort should follow risk, not habit. See GxP risk assessment.

Which applies to you

Work backwards from the activity, not the job title. Ask what regulatory decision the output of this work supports.

  • Output supports releasing a batch to market, or controls how product is made → GMP.
  • Output is a non-clinical safety study submitted to support a regulatory application → GLP.
  • Output involves human subjects in a trial → GCP.
  • Output concerns storage and transport of released product → GDP.
  • Output concerns post-market safety surveillance → GVP.

Most organisations land in more than one. That is normal, and the right response is a common quality backbone with discipline-specific procedures layered on top — not five parallel quality systems. If you are new to the terrain, start with what GxP means.

Where to go next

Explore Cybroscape GxP Copilot for AI-native validation, Cybroscape TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.

Part of our guide to GxP software — categories, evaluation criteria and how the platforms compare. For the detail on this specifically, see what GxP is.

Your shortlist criteria
Fits how you validate (CSV or CSA)Must
Part 11 and Annex 11 records and signaturesMust
Evidence you can export and keepMust
AI features you can actually validateShould
Total cost over three years, validation includedShould
Supplier evidence you can rely onNice
Weights set before demosSo the demo cannot set them for you
A fair comparison weighs the same criteria for every option, and sets the weights before the first demo. Every platform suits some teams; the shortlist is about which one suits yours.
See it on your own systemBring a URS or a system. We run GxP Copilot against it live on the call.
gxp vs gmpgmp glp gcp differencegxp disciplinesdifference between gmp and glpgcp vs gmpgxp types
FAQ

Frequently Asked Questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

What is the difference between GxP and GMP?

GxP is the umbrella category; GMP is one member of it. GMP specifically governs how a product is manufactured — facilities, equipment, batch records, in-process controls and release. GxP also covers GLP for non-clinical safety studies, GCP for clinical trials, GDP for distribution and GVP for post-market safety monitoring.

Is QC laboratory testing GLP or GMP?

Routine quality control testing in a manufacturing laboratory is GMP, not GLP. This is the most common misclassification in the industry. GLP governs non-clinical safety studies submitted to regulators, such as toxicology work, and is distinguished by the Study Director role and an independent Quality Assurance Unit — neither of which exists in GMP in the same form.

Can one company be under GMP, GLP and GCP at once?

Yes, and it is common. A biotech running a clinical trial while manufacturing its own investigational supply operates under GCP and GMP simultaneously. The right response is a common quality backbone — shared document control, audit trail and validation infrastructure — with discipline-specific procedures layered on top, rather than parallel quality systems.

Where do GMP, GLP and GCP overlap?

Four requirements appear in all three: data integrity under ALCOA+, validation of computerised systems, documented personnel training and competence, and control of changes and deviations. This shared core is what makes a single validated platform practical across disciplines.

Which GxP discipline applies to my work?

Work backwards from what regulatory decision the output supports. If it supports releasing a batch or controls how product is made, GMP. If it is a non-clinical safety study for a regulatory application, GLP. If it involves human trial subjects, GCP. If it concerns storage and transport of released product, GDP. If it concerns post-market safety surveillance, GVP.

Keep reading

All articles
ComplianceInspection Readiness for Pharma: FDA & EMA Audit Checklist + Live Inspection Room GuideA practitioner's guide to FDA, EMA and MHRA inspection readiness: how to build an always-ready posture, the 7-item retrieval checklist, live inspection request room tracking (Cybroscape eQMS), and the findings that recur most often. · 8 min readComplianceWhat Is GxP? A Plain-English Guide to GMP, GLP and GCPGxP explained without the jargon: what the letters mean, which rules apply to which work, who enforces them, and what "being GxP compliant" actually requires of a system or a team. · 8 min readComplianceGxP Archiving and Data Retention: The Complete Compliance GuideEverything regulated teams need to know about GxP archiving: retention periods by record type, regulatory requirements, format obsolescence, migration, and the difference between archiving and backup. · 8 min readComplianceGxP Compliance Checklist 2026: 60 Items Across FDA, EMA, and MHRA That Auditors Actually CheckA practitioner-grade GxP compliance checklist covering 21 CFR Part 11, EU Annex 11/22, data integrity, change control, training, and supplier qualification, with pass/fail criteria auditors use. · 7 min readComplianceGxP Risk Assessment: Deciding What Actually Needs ValidatingHow to run a defensible GxP risk assessment: determining GxP impact, scoring severity and detectability under ICH Q9, and using the result to set validation effort instead of validating everything equally. · 7 min readComplianceGxP Roles and Responsibilities: Who Signs What, and WhyThe roles a GxP system depends on (process owner, system owner, QA, IT, validation lead): what each is accountable for, why separation of duties matters, and the handover gaps that cause findings. · 7 min readCompliancePeriodic Review: The Annex 11 Obligation Almost Everyone Is Behind OnPeriodic review is required, routinely overdue, and the fastest way for an inspector to find out that a validated estate stopped being validated. What it is, what it is not, and how to catch up. · 5 min readAgentic AIAgentic AI in regulated environments: patterns that hold up in auditMulti-agent design, tool use, memory, evaluation, with the HITL gate where it counts. · 6 min read

Bring a system. We'll show you the package.

Book a demo, or ask a validation lead a quick question on WhatsApp.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Book a demo

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.